US FDA Agent: What it is, when you need one and how to appoint

Key takeaways

• Who needs it: Non-US manufacturers placing devices on the US market designate a US Agent for FDA communications tied to establishment registration, device listing, and submissions.
• What the Agent does: Receives/forwards FDA notices, coordinates responses, assists with registration & listing actions, and stays reachable during US business hours.
• What it is not: Not an importer of record and not legally responsible for compliance decisions—your QMS and designated officials retain authority.
• Operational success: Defined SLAs, a clear routing matrix, and up-to-date listings prevent delays at audits, inspections, and distributor onboarding.
• Fast start: With prepared artifacts (contacts, product codes, device listings, UDI basics), onboarding can complete in a few business days.

Who needs a US FDA Agent

If you are a non-US manufacturer marketing medical devices in the United States, you designate a US Agent to serve as the primary FDA communications point for establishment registration and device listing, and for certain submission-related interactions. US distributors, importers, or 3PLs do not automatically function as your US Agent unless formally designated.

• Applies to: Class I–III devices, including many IVDs and certain exempt products that are still subject to listing and controls.
• Does not replace: Your regulatory responsibilities, labeling obligations, or the need for a US Importer/UDI compliance.
• Timing: Typically designated during initial market entry or during annual renewal when registration/listing is updated.

Scope & responsibilities (day-to-day)

The US Agent is your communications and coordination hub for FDA interactions. Typical responsibilities include:

• Receiving & forwarding FDA notices: Establishment registration reminders, compliance letters, inquiries, and listing issues.
• Assisting with registration & listing: Ensuring your establishment and device listings are current, accurate, and aligned to product codes and exemptions.
• Coordination during reviews: Supporting interactions on 510(k), De Novo, or other communications, routing requests to the right owner and tracking responses.
• Availability: Remaining reachable in US business hours and providing escalation paths for time-sensitive notices.

The US Agent does not assume legal responsibility for your design/manufacturing decisions. Think of the Agent as the conduit and steward of timely, accurate communications and registration hygiene.

Onboarding artifacts & SLAs (fast start)

1. Contacts & roles: RA/QA owners, submission leads, and management sign-off contacts with availability windows.
2. Establishment & devices snapshot: Current registration status, FEI (if applicable), list of devices with product codes and listing numbers (if any).
3. Escalation matrix & SLAs: Response targets for routine vs urgent FDA notices (e.g., same-day triage, 24–48h owner acknowledgement).
4. Submission context (if pending): 510(k)/De Novo reference numbers, lead reviewers (when known), and expected milestones.
5. Distributor/importer touchpoints: Who needs listing confirmation or letters for onboarding to proceed.

With these ready, US Agent appointment typically completes in 3–5 business days and you avoid back-and-forth during time-sensitive windows.

Registration & Listing essentials (what “good” looks like)

• Accurate establishment details: Legal manufacturer name and address matching labeling and supply chain documentation.
• Device listings aligned to product codes: Ensure exemptions are correctly applied, and listings reflect intended use and technology category.
• Annual renewal readiness: Calendar reminders, change logs, and responsible owners identified before the renewal window.
• Distributor onboarding: Provide listing confirmations quickly—many partners treat delays as a red flag.

Submissions & communications flow

When submissions or review communications occur, define a clear flow so nothing stalls:

1. US Agent receives an FDA communication (or platform alert) and logs the item.
2. Agent routes to the named owner (RA/Clinical/Engineering) within the SLA and tracks acknowledgement.
3. Owner drafts response; Agent checks formatting/routing requirements and sends back through the official channel.
4. Agent confirms FDA receipt and records the closure or next action date.

This model avoids “lost emails” and ensures FDA time-bound actions are met even across time zones.

Evidence to keep & what auditors expect

• US Agent appointment documentation (contract/letter), availability window, and routing matrix.
• Registration/listing records and change logs; confirmation of successful updates/renewals.
• Communications log with response dates, owners, and outcomes.
• Training/awareness for internal staff on how to engage the Agent and meet SLAs.

Common pitfalls & how to avoid them

• “Silent” mailbox: Agent not reachable or slow to relay messages. Fix with SLAs, backups, and clear escalation.
• Out-of-date listings: Product codes, names, or exempt status not maintained; slows audits and onboarding. Maintain a single source of truth and periodic checks.
• Role confusion: Assuming the Agent is importer or responsible for submissions. Keep responsibilities documented and trained.
• Renewal surprises: Missing calendar entries and ownership → last-minute scramble. Automate reminders and designate alternates.

Worked examples

FAQ